Details for New Drug Application (NDA): 206935
✉ Email this page to a colleague
The generic ingredient in IRINOTECAN HYDROCHLORIDE is irinotecan hydrochloride. There are thirty-three drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the irinotecan hydrochloride profile page.
Summary for 206935
| Tradename: | IRINOTECAN HYDROCHLORIDE |
| Applicant: | Novast Labs |
| Ingredient: | irinotecan hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 206935
| Mechanism of Action | Topoisomerase Inhibitors |
Suppliers and Packaging for NDA: 206935
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| IRINOTECAN HYDROCHLORIDE | irinotecan hydrochloride | INJECTABLE;INJECTION | 206935 | ANDA | Ingenus Pharmaceuticals, LLC | 50742-401 | 50742-401-02 | 1 VIAL, GLASS in 1 CARTON (50742-401-02) / 2 mL in 1 VIAL, GLASS |
| IRINOTECAN HYDROCHLORIDE | irinotecan hydrochloride | INJECTABLE;INJECTION | 206935 | ANDA | Ingenus Pharmaceuticals, LLC | 50742-402 | 50742-402-05 | 1 VIAL, GLASS in 1 CARTON (50742-402-05) / 5 mL in 1 VIAL, GLASS |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 40MG/2ML (20MG/ML) | ||||
| Approval Date: | May 26, 2017 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 100MG/5ML (20MG/ML) | ||||
| Approval Date: | May 26, 2017 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
